



INFLAMMATORY BOWEL DISEASE



MEDDOCS
— International —

Anti-Inflammatory Potential of Lichens and its Substances

Ha Thi Nguyen^{1,2}; Alekhya Ketha³; Biljana Kukavica⁴; Vinay Bharadwaj Tatipamula^{1,2*}

¹Institute of Research and Development, Duy Tan University, 03 Quang Trung, Da Nang 550000, Vietnam.

²Faculty of Medicine, Duy Tan University, 03 Quang Trung, Da Nang 550000, Vietnam.

³Pharmaceutical Chemistry Department, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530003, Andhra Pradesh, India.

⁴Faculty of Natural Sciences and Mathematics, University of Banja Luka, 2 Mladena Stojanovića St, 78000 Banja Luka, Bosnia and Herzegovina.

Corresponding Author: Vinay Bharadwaj Tatipamula

Institute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam.

Tel: +84-774562619;

Email: vinaybharadwajtatipamula@duytan.edu.vn

Abstract

Lichen is a symbiotic form of a mycobiont and a photobiont or a cyanobiont. In the folk medicine of different cultures, they are used to treat multiple conditions such as wounds, skin disorders, respiratory and digestive problems, inflammation and its complications. Medicinal applications of lichens are documented in Ayurveda, Unani, and Doctrine of Signature with the contribution of knowledge from traditional medicinal practitioners. In Asia and Europe, lichens are taken orally as a decoction to treat inflammation-related ailments. This review summarized the genera of lichens used in traditional medicine of different cultures across the world and also listed out the folk names of lichen species that have anti-inflammatory activity. In addition, the anti-inflammatory potential of lichen extracts and their substances are also discussed.

Published Online: Jan 25, 2021

eBook: Inflammatory Bowel Disease

Publisher: MedDocs Publishers LLC

Online edition: <http://meddocsonline.org/>

Copyright: © Vinay Bharadwaj T (2021).

This Chapter is distributed under the terms of Creative Commons Attribution 4.0 International License

Keywords: Lichens; Anti-inflammation; Lichen metabolites; Lichen chemistry; Lichen biology; Traditional medicine.

Introduction

Lichen (leikhēn means “what eats around itself”), is a symbiosis between a mycobiont (heterotropic fungi) and a photobiont (photosynthetic algae) or a cyanobiont (cyanobacteria) where the mycobiont involves in chemical signaling and provides shape and structure, while the photobiont/cyanobiont supply nutrient exchange, i.e., carbohydrates [1,2]. The taxonomy of lichens is defined based on mycobiont content since it proportionally accounts for 95-98% and plays a crucial role in the sexual reproduction of lichens. Lichens can be differentiated from fungi based on its photobiont content [3].

Generally, the growing rate of lichens is found to be less than 1 cm/year, which is the lowest among the plant kingdom [3,4]. It is interesting to note that lichens are epiphytes as they synthesize their food by photosynthesis using plants, asphalt, sand, leaf litter, roof materials, rocks, and dead logs as substrates. Mostly, lichens are deliberated as “pioneer” species and highly persist in terrestrial environments and rarely in freshwater or marine ecosystems [5]. As the lichens are generally termed as bio-monitors, they are very less resistant towards pollution and acid rains that contain high amounts of sulfur dioxide. Around



20,000 lichens have been identified across the world so far, containing mostly ascomycetes and basidiomycetes, and deuteromycetes to a much lesser extent. The thallus is a unique characteristic of lichens, which is usually a multicellular structure categorizing into crustose, leprose, foliose, filamentous, and fruticose [6].

Lichens are well-recognized for their medicinal applications. The majority of lichens are used in the traditional medicines of arctic and temperate areas and fewer in the tropics. About 60 genera of lichens are widely used in folk medicine by different cultures worldwide. Among all, the *Usnea* genus is the most widely used species [7]. As external agents, lichens have been widely used for dressing wounds, stopping bleeding, and topically for sores and skin infections [8–10]. In the form of extracts and decoction, lichens served to treat multiple ailments such as asthma, backache, bronchitis, colds, cough, diarrhea, eye infections, expel intestinal worms, fever, heartburn, inflammation associated with diabetes, intestinal problems, loss of appetite, lung diseases, neuralgia, malaria, respiratory problems, rheumatism, sickness, swelling, typhoid, vaginal discharge, etc [10-16]. In this book chapter, the roles of lichens in traditional medicine were discussed, followed by a discussion on the anti-inflammatory effects of lichens' extracts and compounds.




Figure 1: Metabolic pathway of arachidonic acid.

Inflammation

Inflammation is characterized by the stimulation of the host's non-immune and immune cells in response to infections and/or toxins in order to eradicate pathogens and stimulate tissue healing and recovery [17]. Based on the degree and extent of an inflammatory response, inflammation is classified into three subtypes, namely acute, sub-acute, and chronic inflammation. Acute inflammation is a short-term (1-3 days) illness or injury characterized by loss of function, heat, pain, redness, and swelling. Sub-acute inflammation can continue for 3-30 days, and if not resolved within 30 days, it develops into chronic inflammation that lasts for several months or years and is linked to many deadly diseases, such as allergies, cardiovascular diseases, cancer, diabetes, psoriasis, and rheumatoid arthritis [18].

Cytokines and autacoids play a key role in the inflammatory responses. Cytokines such as Interferon γ (INF- γ), Tumor Necrosis Factor α (TNF- α), and Interleukins (IL), have a complex role in inflammation [19,20]. Autacoids include eicosanoids (e.g. Leukotrienes (LTs), Prostaglandins (PGs), Phospholipids (PLs), Prostacyclins (PCs), and Thromboxanes (TXs) and Platelet-Acti-

tivating Factors (PAFs) [21]. Eicosanoids are synthesized from arachidonic acid (a 20-carbon polyunsaturated fatty acid) by activated leukocytes, platelets, and mast cells that are distributed widely in the human body. Additionally, eicosanoids are produced by bradykinin, TNF- α , and some hormones either indirectly by an accumulation of intracellular levels of Ca^{+2} ions or directly by activation of PLA2 that hydrolyzes arachidonic acid [22]. An increase in Ca^{+2} concentration is generally achieved by cell membrane damage, while activation of PLA2 is metabolized by two enzymatic pathways, such as Cyclooxygenase (COX) and Lipoxygenase (LOX) pathways [23].

Arachidonic acid is oxygenated into cyclic endoperoxide PGG2 in the presence of COX enzymes (prostaglandin-endoperoxide synthase), which is converted to the closely related PGH2. Due to their unstable nature, these byproducts are further converted into PGE1, PGE2, PGF2 α , PGI1, and TXA2. Notably, PGE1, PGE2, and PGI1 are strong arteriolar dilators that increase the small-vein permeability, thereby enhance the effects of other pain-provoking mediators such as histamine and bradykinin. PGs and TXs can cause vasoconstriction and smooth muscle contraction, while TXA2 is an effective platelet-aggregating agent that is involved in the formation of thrombus [24-26] (Figure 1). On the other hand, LOX enzymes (5-LOX, 8-LOX, 12-LOX, and 15-LOX) oxidize arachidonic acid into 5-hydroperoxy eicosatetraenoic acid that, in turn, will be converted into leukotriene A4 (LTA4). LTA4 stimulates LTB4, LTC4, LTD4, and LTE4 cascade. Activated LTB4 binds to its receptors to activate phosphatidylinositol 3-kinase and Nuclear Factor kappa B (NF- κ B) pathway, while LTC4, LTD4, and LTE4 bind to cysteinyl LT receptors, thereby regulate the NF- κ B pathway. Particularly, LTC4 activates p50-65 complex by phosphorylating NF- κ B p65 [27-29] (Figure 1).

Initially, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as aspirin, diclofenac, ibuprofen, and naproxen are widely used for inhibiting the COX-1/2 enzymes non-selectively [30]. These drugs, however, cause severe gastrointestinal problems. Later, selective COX-2 inhibitors, namely celecoxib and rofecoxib, with fewer side effects, are commonly used to treat inflammation and pain. Prolonged usage of selective COX-2 inhibitors, unfortunately, brings cardiovascular problems [31]. On the other hand, certain anti-asthmatic drugs are used as potential LOX inhibitors, such as marketed drugs, meclofenamate sodium, and zileuton [32,33].

Anti-inflammatory potential of lichens

Lichens species used for inflammation in traditional medicine

Lichen, in Greek "leprous," refers to a drug that treats skin diseases, especially skin peeling [34]. Since the 15th century, the usage of several lichen species such as *Usnea*, *Cladonia*, *Evernia*, *Parmelia*, *Lobaria*, *Pertusaria*, *Peltigera*, *Rocella*, *Physcia*, and *Xanthoria* was documented in Ayurveda, Western Medical Herbalism, Traditional Chinese Medicine, Unani, Doctrine of Signature and Homeopathy. Remarkably, during the 18th dynasty *Evernia furfuracea* (L.) Mann belongs to the *Parmeliaceae* family was marketed as the first drug for treating microbial infections [35]. During middle age, medicinal practitioners prominently used lichens as herbs for inflammation, coughs, skin problems, and rabies [36]. The folk names of different lichen species used to treat inflammation-related conditions were listed in Table 1.

Table 1: The use of lichen species in traditional medicine for treating inflammation.

Species	Folk name	Culture (Location)	Ref
<i>Cladina rangiferina</i> (L.) Nyl.	Whapskumuk or ephstatuk	Whapmagoostui Cree (Quebec, Canada)	[37]
<i>Dendrocosticta wrightii</i> (Tuck.) B. Moncada and Lücking	Shēn bēi niúpí yè or lǎo lóng pí or kuān yè niúpí yè	Ancient China	[7]
<i>Evernia mesomorpha</i> Nyl.	Biǎn zhī yī	Ancient China	[7]
<i>Letharia vulpina</i> (L.) Hue	Laxpt or maqa'hl Ōl-gät'-i	Umatilla and Cayuse (Oregon, USA) Yuki and Wailaki (CA, USA)	[38]
<i>Lethariella cladonioides</i> (Nyl.) Krog	Gangge Jīn shuā bǎ	Tibet Naki (China)	[7,39]
<i>Lethariella sinensis</i> Wei and Jiang	-	Naki (China)	[39]
<i>Lobaria isidiosa</i> (Müll. Arg.) Vain.	Lǎo lóng pí or shānhú yá fèi yī	Ancient China	[10]
<i>Lobaria pulmonaria</i> (L.) Hoffm.	Fèi yī or dōu yī or há mǎ qī or niúpí yè or shí lóng yī or shí lóng pí	Ancient China	[10]
<i>Lobaria sublaevis</i> (Nyl.) Yoshim.	Yà píng fèi yī or lǎo lóng pí	Ancient China	[7]
<i>Masonhalea richardsonii</i> (Hook.) Kärnefelt	Tlingit	Tlingit (Alaska, USA)	[40]
<i>Ophioparma ventosa</i> (L.) Norman	Hóng pán yī or shí shuāng or chì xīng yī	Ancient China	[7]
<i>Parmelia omphalodes</i> (L.) Ach.	Crottle, crotal, dark crottle, or fiasgag nancreag	Britain	[41]
Parmelioid lichens	Urth Lucca	Lëpushë (Albania) Lucca (Italy)	[42,43]
<i>Parmotrema nilgherrense</i> (Nyl.) Hale	Charila	Ayurvedic medicine (India)	[12]
<i>Parmotrema saccatilobum</i> (Taylor) Hale	-	Milne Bay (Papua New Guinea)	[44]
<i>Parmotrema subtinctorium</i> (Zahlbr.) Hale	Yà dà yè méi or yà ránliào méi yī	Ancient China	[7]
<i>Parmotrema tinctorum</i> (Nyl.) Hale	Dà yè méi or bái shí huā or shí huā or méi yī or shí yī or há má pí	Ancient China	[7]
<i>Punctelia borreri</i> (Sm.) Krog	Fēn bǎn xīng diǎn méi or fēn bǎn méi yī	Ancient China	[7]
<i>Ramalina conduplicans</i> Vain.	Yīng zhī shù huā or shù huā or shù xū or shí huācài	Yi, Dai, and Han (s. Yunnan, China)	[7]
<i>Ramalina roesleri</i> (Hochst.) Hue	Ròuci shù huā	Ancient China	[7]
<i>Ramalina</i> spp. Ach.	Λειχήν or βρύον	Ancient Greece	[45]
<i>Roccella</i> sp.	Phýkos thalássion or gnomeusilum	Ancient Greece	[7]
<i>Stereocaulon paschale</i> (L.) Hoffm.	Wapskirknok	Mistissini Cree (Quebec)	[37]
<i>Sulcaria sulcata</i> (Lév.) Bystrek ex Brodo and D. Hawksw.	Tóufǎ qī or gōu shù fā	Naki (China)	[7]
<i>Thamnolia subuliformis</i> (Ehrh.) W. Culb.	Xuě di chá or tàibái chá or shí bái chá or tàibái zhēn or bái xuě chá or xuě chá	Nakhi (nw Yunnan, China)	[39]
<i>Thamnolia vermicularis</i> (Sw.) Ach. ex Schaerer	De chá or tàibái chá or shí bái chá or tàibái zhēn or tàibái cài or bái xuě chá or huí yàng dìyī	Nakhi (nw Yunnan, China)	[39]
<i>Umbilicaria nanella</i> Frey et Poelt	Xiǎo hēi fù shí ěr or hēi qí yī or hēi shí ěr zi or liè yè shí ěr or pán xíng shí ěr	Ancient China	[7]
<i>Usnea aciculifera</i> Vain.	Jiān cì sōng luó Sajasta	Ancient China Criollos (Dry Chaco, Argentina)	[7,46]
<i>Usnea barbata</i> (L.) Weber ex F.H. Wigg.	Tai angin	Karo (Indonesia)	[47]
<i>Usnea ceratina</i> Ach.	Jiǎo sōng luó or hóng suǐ sōng luó	Ancient China	[7]
<i>Usnea densirostra</i> Taylor	Yerba de la piedra, barba de piedra	Argentina	[48]
<i>Usnea diffracta</i> Vain.	Huán liè sōng luó or sōng jīn téng or sōng luó	Jianghua (China)	[10]
<i>Usnea florida</i> (L.) F. H. Wigg.	Huā sōng luó	Ancient China	[7]
<i>Usnea longissima</i> Ach.	Jianmingyan	Lisu (nw Yunnan, China)	[49]
<i>Usnea pectinata</i> Tayl.	Nǐ zhǎng sōng luó or dà péng cǎo or bǐchǐ sōng luó	Ancient China	[7]

Usnea spp. Dill. ex Adans.	Ushna or shaibat-al-ajooz (Unani medicine) Sōng luó or nǚ luó Oak moss; tree moss	Muslim culture (India) Ancient China Europe	[50-52]
Usnea subfloridana Stirt.	Yà huà sōng luó	Ancient China	[7]
Usnea trichodeoides Vain.	Cūpí sōng luó or tiānpéng cǎo or biàn hóng zhǎng sōng luó or shù fā qī Liquen de bosc Islandski lišaj, islandska mahovina; mašina Tripoli	Ancient China Pallars (Spain) Lukomir (Bosnia and Herzegovina) Tripoli (Lebanon)	[7,9,53,54]
Varicellaria velata (Turner) Schmitt and Lumbsch	Bāo bèi jī píyī or shí xiāng	Ancient China	[7]
Xanthoparmelia conspersa (Ehrh. ex Ach.) Hale	Ubulembu belitye -	Xhosa (South Africa) Iroquois (Ontario, Canada)	[55,56]
Xanthoparmelia convoluta (Kremp.) Hale	-	Khoikhoi (Namibia)	[56]
Xanthoparmelia hottentotta (Ach.) A. Thell et al.	-	Khoikhoi (Namibia)	[56]
Xanthoparmelia spp. (Vain.) Hale	Tschétláat or nihałá-d or céłá-d Owa'si or owa'huru'suki -	New Mexico Navajo (Arizona) Hopi (Arizona, USA)	[7,57]
Xanthoparmelia tinctina (Maheu and Gillet) Hale	Àn fù huáng méi or àn fù méi yī	Ancient China	[7]

Lichens extracts tested for anti-inflammatory activity

Lichens have long been considered as valuable sources to cure various conditions for humans and are also used as key ingredients in dyes and perfumes. Also, the medicinal properties of lichens are well-documented in Ayurveda, Unani, and Doctrine of Signature. Based on this evidence, scientists screened lichen extracts for various biological activities and determined their potentiality to treat various ailments. The studies on the anti-inflammatory potentiality of various lichen extracts are listed in Table 2.

The extracts of *Cladonia clathrate*, *Lobaria pulmonaria*, and *Teloschistes flavicans* were tested for anti-inflammatory activity using carrageenan-induced animal models [58-60]. The hydroalcoholic extract of *C. clathrate* was found to have significant inhibition in both rat paw edema and mice peritonitis induced by carrageenan [58]. Aqueous extract of *L. pulmonaria* showed moderate activity in paw edema and granuloma models as compared to standard drugs (nimesulide and indomethacin) [59]. Extracts of *T. flavicans*, on the other hand, were reported to have anti-edematogenic activity in the rat paw edema model but not effective on subchronic inflammation models [60].

Ingolfsdottir group (1994 & 1996) investigated the COX and 5-LOX inhibitory capacity of different extracts from *Cetraria islandica* and *Stereocaulon alpinum* and found that phenolic

rich extract of *S. alpinum* has potent inhibition on both COX and 5-LOX, while petroleum ether and methanol extracts of *C. islandica* were selectively active against LOX enzymes [61,62]. The studies of COX inhibition of various extracts of *Gyrophora exculenta* presented their prominent inhibitory effects on PGH2 synthase [63].

Our group, over several years, has tested extracts of *Dirinaria consimilis*, *Graphis ajarekarii*, and *Roccella montagnei* against rat paw edema induced by formalin at two different doses. At both doses, the acetone extract of *D. consimilis* was reported to have more reduction in paw edema than chloroform extract of that species [64]. Hydroalcoholic extract of *G. ajarekarii* showed prominent activity than ethyl acetate extract from the same species [65]. On the other hand, acetone extract of *R. montagnei* was noticed to have a noticeable reduction in rat paw edema than standard [66]. Additionally, the investigation of extracts of *D. consimilis* and *G. ajarekarii* against protein denaturation found that only ethyl acetate and acetone extracts of both species were more active than chloroform and methanol extracts [67].

Also, other research group has investigated the anti-inflammatory activity of hydroalcoholic extract of *Usnea barbata* and *Usnea hirta* and revealed the equivalent activity of these extracts compared to that of the standard drugs phenylbutazone and hydrocortisone hemisuccinate [68].

Table 2: Lichen extracts with anti-inflammatory activities.

Lichen	Extract(s)	Bioassay	Pharmacological activity	Ref
<i>Cladonia clathrata</i>	Hydroalcoholic extract	Carrageenan-induced rat paw edema and peritonitis in mice	Significant activity in both bioassays.	[58]
<i>Cetraria islandica</i>	Petroleum ether, methanol and water extracts	5-LOX and COX inhibitory assay	Petroleum ether and methanol extracts exhibited pronounced activity in the 5-LOX assay and no activity on COX up to 50 µg/ml.	[61]
<i>Dirinaria consimilis</i>	Chloroform and acetone extracts	Formalin-induced rat paw edema	Acetone extract showed more reduction in paw edema than chloroform extract.	[64]
<i>Dirinaria consimilis</i> and <i>Ramalina leiodea</i>	Chloroform, ethyl acetate, acetone and methanol extracts	Protein denaturation	Ethyl acetate and acetone extracts of both species showed a prominent inhibitory profile against protein denaturation.	[67]

Graphis ajarekarii	Ethyl acetate hydroalcoholic extract	Protein denaturation and formalin-induced albino rat paw edema	In both bioassays, the hydroalcoholic extract showed prominent activity than ethyl acetate extract.	[65]
Gyrophora exulenta	Methylene chloride, ethyl acetate, and n-butanol extracts	COX activity (seminal sheep vesicle)	A prominent inhibitory effect on COX activity of prostaglandin H ₂ synthase.	[63]
Lobaria pulmonaria	Aqueous extract	Carrageenan-induced paw edema, and cotton pellet granuloma	At tested doses, the aqueous extract of L. pulmonaria showed moderate activity compared to standard in both assays.	[59]
Roccella montagnei	Acetone extract	Formalin-induced rat paw edema	A prominent reduction in rat paw edema was observed.	[66]
Stereocaulon alpinum	-	5-LOX and COX inhibitory assay	Phenolic containing extract of S. alpinum showed potent activity on 5-LOX and COX.	[62]
Usnea barbata and Usnea hirta	Hydroalcoholic extract	Anti-inflammatory activity	The anti-inflammatory activity of both extracts was comparable with the standard.	[68]
Teloschistes flavicans	Diethyl ether, chloroform, and acetone extract	Carrageenan-induced rat paw edema and cotton pellet induced granulomatous lesion	The ethereal, chloroform and acetone extracts have anti-edematogenic activity but not effective on subchronic inflammation.	[60]

Lichen active substances against inflammation

Lichens produce unique substances, which may help them to survive in extreme environments. By using mevalonate, acetyl-polymalonate, and shikimic acid pathways, lichens produce a diverse range of secondary metabolites, which are termed as "Lichen substances". All lichen substances are produced by mycobiont and accumulated in the hyphae, cortex or medullary layer to protect them from pathogens and external abiotic factors [59].

The systemic study of the chemistry of lichens and their substances was initiated in 1907 by a German scientist, Friedrich Wilhelm Zopf [69]. Later, several scientists applied chromatography techniques towards the lichen, which resulted in the isolation and elucidation of about 1050 unique substances [70]. Biosynthetically, lichen substances were divided into two groups: Primary (intracellular) and secondary (extracellular) metabolites. The primary metabolites include proteins, amino acids, carotenoids, polysaccharides, and vitamins found in the protoplasts and cell walls [69,71], while the secondary metabolites include phenolic compounds, terpenes, alkaloids. Chemically, lichen substances are categorized into two classes (a) aliphatic substances that contain mononuclear phenolic compounds, aliphatic and phenolic acids, and zeirin analogs and (b) aromatic substances that include depsides, depsidones, diketopiperazines, dibenzofurans, pulvic acids, quinones, and xanthenes [59].




Figure 2: Chemical structure of lichen substances reported to have anti-inflammatory properties.

Lichen secondary metabolites exhibit antimicrobial [72,73], anti-tubercular [72], antioxidant [66], anti-inflammatory [74], fibrinolytic [65], cytotoxic [75], and antidiabetic [76] properties and could be used as sources of pharmaceutical chemicals. Lichen substances with anti-inflammatory activity are presented in Table 3, and their chemical structures are represented in Figure 2 and Table 4. Several groups investigated the potentiality of nearly 70 lichen substances against inflammation using protein denaturation, carrageen-induced models, immune enzyme assays, as well as COX, 5-LOX, LTB₄ biosynthesis, and PG biosynthesis inhibitory activities [61,66,74,77-82]. Ingólfssdóttir and colleagues (1996 & 1997) tested two depsides (atranorin & baeomycesic acid) and a depsidone (lobaric acid) against 5-LOX and COX inhibitory assays and found that lobaric acid was active, while atranorin was inactive on both enzymes [62,81]. On the other hand, baeomycesic acid was specifically active against 5-LOX [81]. This group has also investigated the 5-LOX inhibitory property of (+)-protolichesterinic acid isolated from *Cetraria islandica* and revealed its dose-dependent inhibitory effects [61]. Sankawa group (1982) tested forty commercially available depsides and depsidones for their ability to inhibit PG biosynthesis using rabbit renal microsomes and reported that depside, 4-O-methylcryptochlorophaeic acid, was the most active one [78]. Additionally, the kinetic studies of this depside revealed its function as a competitive inhibitor of PG biosynthesis [77]. Later, seven lichen substances were isolated from *Parmelia* species and tested for LT B₄ biosynthesis inhibitory activity [80]. Among those, only atranorin, diffractaic acid (+)-protolichesterinic acid showed significant inhibition of LT B₄ biosynthesis in polymorphonuclear leukocytes, while other compounds were found to be either weak or inactive [80]. Gissurarson group (1997) isolated lobaric acid from *Stereocaulon alpinum*, evaluated its enzyme immunoassay using cysteinyl-LT and reported its effectiveness at 5.5 μM dose [82].

Tatipamula group isolated about fifteen lichen substances from *Dirinaria consimilis* [74], *Graphis ajarekarii* [65], *Roccella montagnei* [66], and *Ramalina leiodea* [83] and tested for protein denaturation inhibitory activity. All the tested metabolites showed moderate inhibitory activity against albumin protein denaturation with IC₅₀ values ranging from 330-950 μg/mL as compared to the standard drug, indomethacin [65,74,84]. This group has also compared the potency of atranorin (a depside) with ribenone (a diterpene) in the formalin-induced albino rat paw edema model and found that atranorin showed prominent

activity than ribenone [65]. The anti-inflammatory potency of atranorin has also been tested by another group in carrageenan-induced rat models, which showed significant activity in paw edema, as well as leukocyte migration in rats as compared to standard [79].

Table 3: Lichen substances that possess anti-inflammatory activity.

Lichen substance	Source	Bioassay	Pharmacological activity	Ref
(+)-Protolichesterinic acid	<i>Cetraria islandica</i>	5-LOX inhibitory assay	Dose-dependent inhibitory effects	[61]
Forty depsides and depsidones	-	PG biosynthesis inhibitory assay	4-O-methylcryptochlorophaeic acid was the most active and competitive inhibitor.	[77,78]
Antarvediside A-B, sekikaic acid, atranorin, divaricatic acid and 2'-O-methyl divaricatic acid	<i>Dirinaria consimilis</i>	Protein denaturation inhibitory assay	Moderately active as compared to indomethacin	[74]
Atranorin	<i>Cladina kalbii</i>	Carrageenan-induced rat models	It showed significant inhibitory effect on carrageenan-induced rat paw edema and leukocyte migration.	[79]
Atranorin and lobaric acid	<i>Stereocaulon alpinum</i>	5-LOX and COX assays	Lobaric acid: IC ₅₀ values of 7.3 (5-LOX) and 29.2 (COX) μM Atranorin: Inactive on both enzymes	[62]
Atranorin and ribenone	<i>Graphis ajarekarii</i>	Protein denaturation assay and formalin-induced rat paw oedema	In both bioassays, atranorin showed prominent activity than ribenone	[65]
Atranorin, diffractaic acid, (+)-protolichesterinic acid, ethyl hematommate, (+)-usnic acid, methyl β-ornicolcarboxylate and gyrophoric acid	<i>Parmelia nepalensis</i> and <i>Parmelia tinctorum</i>	LT B4 biosynthesis inhibitory assay	Only atranorin, diffractaic acid, and (+)-protolichesterinic acid were active.	[80]
Baeomycesic acid	<i>Thamnolia subuliformis</i>	5-LOX and COX inhibitory assays	The IC ₅₀ value 8.3 μM on 5-LOX and inactive on COX	[81]
Divarinolmonomethylether, ethyl divaricinate, divarinol, orcinol, methyl 2,6-dihydroxy-4-methylbenzoate, haematommic acid, atranol, ethyl haematommate and ethyl orsellinate	<i>Roccella montagnei</i>	Protein denaturation inhibitory assay	Moderately active as compared to indomethacin	[66]
Lobaric acid	<i>Stereocaulon alpinum</i>	Enzyme immunoassay	The ED ₅₀ of 5.5 μM on cysteinyl-leukotriene formation in the smooth muscle taenia coli from guinea pigs.	[82]
Methyl 2,6-dihydroxy-4-methyl benzoate, haematommic acid and ethyl haematommate	<i>Ramalina leiodea</i>	Protein denaturation inhibitory assay	Moderate active compared to indomethacin	[83]

Table 4: Mononuclear phenolic compounds from lichens possessing anti-inflammatory activity.

Lichen substance	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
2,4-Dihydroxy-6-pentylbenzoic acid	COOH	OH	H	OH	H	n-C ₅ H ₁₁
2,4-Dimethoxy-6-pentylbenzoic acid	COOH	Me	H	Me	H	n-C ₅ H ₁₁
2-Hydroxy-4-methoxy-6-pentylbenzoic acid	COOH	OH	H	Me	H	n-C ₅ H ₁₁
2-Hydroxy-6-pentylbenzoic acid	COOH	OH	H	H	H	n-C ₅ H ₁₁
Atranol	Me	H	OH	CHO	OH	H

Divarinol	n-C ₃ H ₇	H	OH	H	OH	H
Divarinolmonomethylether	OH	H	OH	H	OMe	H
Ethyl divaricatinatate	n-C ₃ H ₇	COOC ₂ H ₅	OH	H	OMe	H
Ethyl haematommate	Me	COOC ₂ H ₅	OH	CHO	OH	H
Ethyl orsellinate	Me	COOC ₂ H ₅	OH	H	OH	H
Haematommic acid	Me	COOH	OH	CHO	OH	H
Methyl-2,6-dihydroxy-4-methylbenzoate	Me	H	OH	COOMe	OH	H
Methyl-β-orcinolcarboxylate	COOMe	OH	CHO	OH	H	Me
Orcinol	Me	H	OH	H	OH	H

Conclusions

The inflammation process, though a self-limiting process, can become chronic and can further lead to several other severe inflammatory conditions such as cancer, atherosclerosis, Alzheimer's, and rheumatoid arthritis. This review provided an overview on the effectiveness of lichens on anti-inflammation based on the current knowledge on traditional medicine as well as pharmacological studies. However, the available studies on this topic remain limited, which require a thorough chemical and pharmacological investigation of anti-inflammatory agents from lichens. The current review provides an overview on the topic to aid the investigators in designing and performing further pharmacological studies on lichens to fill these gaps.

References

1. Hammer S. Lichens. In: Encyclopedia of microbiology. Elsevier. 2009: 142-152.
2. Zambare VP, Christopher LP. Biopharmaceutical potential of lichens. *Pharm. Biol.* 2012; 50: 778-798.
3. Shukla V, Joshi GP, Rawat MSM. Lichens as a potential natural source of bioactive compounds: A review. *Phytochem. Rev.* 2010; 9: 303-314.
4. Bharadwaj VT, Sastry G V, Murthy K. A note on the occurrence of lichens on Vainateya Godavari mangroves in East Godavari district of Andhra Pradesh India. *Stud. Fungi.* 2018; 3: 302-308.
5. Tatipamula VB. Chemical and pharmacological evaluation of manglicolous lichens. 1st ed. LAP LAMBERT Academic Publishing: Mauritius, 2019.
6. Bharadwaj VT. New record of mangrove lichens from Andhra Pradesh and Orissa states of India. *Stud. Fungi.* 2019; 4: 97-100.
7. Crawford SD. Lichens used in traditional medicine. In: Lichen secondary metabolites. Springer International Publishing: Cham. 2015: 27-80.
8. Shah NC. Lichens of economic importance from the hills of Uttar Pradesh, India. *J. Herbs. Spices. Med. Plants.* 1997; 5: 69-76.
9. Ferrier J, Saciragic L, Trakić S, Chen ECH, Gendron RL, et al. An ethnobotany of the Lukomir Highlanders of Bosnia & Herzegovina. *J. Ethnobiol. Ethnomed.* 2015; 11: 81.
10. Hempen CH, Fischer T. A materia medica for Chinese medicine. Elsevier. 2009.
11. Pardanani DS, DeLima RJ, Rao RV. Study of the effects of Speman on semen quality in oligospermic men. *Indian. J. Surg.* 1976; 38: 34-39.
12. Kumar K. *Parmelia* spp. (lichens) in ancient medicinal plant lore of India. *Economic. Botany.* 2001; 55: 458-459.
13. O'Neill AR, Badola HK, Dhyani PP, Rana SK. Integrating ethnobiological knowledge into biodiversity conservation in the Eastern Himalayas. *J. Ethnobiol. Ethnomed.* 2017; 13: 21.
14. Singh H, Husain T, Agnihotri P, Pande PC, Iqbal M. Biodiversity conservation through traditional beliefs system: A case study from Kumaon Himalayas, India. *Int. J. Conserv. Sci.* 2012; 3: 33-40.
15. Chandler RF, Leighton AL. Wild plant use by the woods Cree (Nihithawak) of East-Central Saskatchewan. *Anthropologica.* 1988; 30: 219.
16. Black PL, Arnason JT, Cuerrier A. Medicinal plants used by the Inuit of Qikiqtaaluk (Baffin Island, Nunavut). *Botany.* 2008; 86: 157-163.
17. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, et al. Chronic inflammation in the etiology of disease across the life span. *Nat. Med.* 2019; 25: 1822-1832.
18. Lordan R, Tsoupras A, Zabetakis I. Inflammation. In: The impact of nutrition and statins on cardiovascular diseases. Elsevier. 2019: 23-51.
19. Malik STA, Balkwill FR. Cytokines. In: The nude mouse in oncology research. CRC Press. 2018.
20. Zhang JM, An J. Cytokines, inflammation, and pain. *Int. Anesthesiol. Clin.* 2007; 45: 27-37.
21. Giera M, Galano JM. Eicosanoids. In: Encyclopedia of analytical science. Elsevier. 2019.
22. Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends Mol. Med.* 2008; 14: 461-469.
23. Smith WL, Murphy RC. The eicosanoids: Cyclooxygenase, lipoxygenase and epoxygenase pathways. In: Biochemistry of lipids, lipoproteins and membranes: Sixth edition. Elsevier. 2015.
24. Smyth EM, FitzGerald GA. The eicosanoids: Prostaglandins, thromboxanes, leukotrienes, and related compounds. 2012: 313-329.
25. Stanley D. Prostaglandins and other eicosanoids in insects: Biological significance. *Annu. Rev. Entomol.* 2006; 51: 25-44.
26. Agarwal S, Reddy GV, Reddanna P. Eicosanoids in inflammation and cancer: The role of COX-2. *Expert. Rev. Clin. Immunol.* 2009; 5: 145-165.
27. Nakamura M, Shimizu T. Leukotriene receptors. *Chemical Reviews.* 2011; 111: 6231-6298.
28. Powell WS, Rokach J. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. *BBA-Mol. Cell. Biol. L.* 2015; 1851: 340-355.

29. Brock TG. Regulating leukotriene synthesis: The role of nuclear 5-lipoxygenase. *J. Cell. Biochem.* 2005; 96: 1203-1211.
30. Livingston A. Mechanism of action of nonsteroidal anti-inflammatory drugs. *Vet. Clin. North. Am-Small. Anim. Pract.* 2000; 30: 773-781.
31. FitzGerald GA. Coxibs and cardiovascular disease. *N. Engl. J. Med.* 2004; 351: 1709-1711.
32. Bruno F, Spaziano G, Liparulo A, Roviezzo F, Nabavi SM, et al. Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma. *Eur. J. Med. Chem.* 2018; 153: 65-72.
33. Israel E. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. *Ann. Intern. Med.* 1993; 119: 1059-1066.
34. Ashton H. *The royal horticultural society new encyclopedia of herbs & their uses (revised edition)*. London: Dorling Kindersley. 2002.
35. Watts DC. *The Hamlyn guide to edible and medicinal plants of Britain and Northern Europe*. Biochem. Soc. Trans. 1983.
36. Pereira J. *The elements of materia medica and therapeutics*. Cambridge University Press: Cambridge. 2014.
37. Fraser MH. Ethnobotanical investigation of plants used for the treatment of type 2 diabetes by two Cree communities in Québec: Quantitative comparisons and antioxidant evaluation. *ProQuest Dissertations and Theses*. 2006.
38. Simms SR, Hunn ES, Salinas M. Nach'i-Wana, 'The big river': Mid-Columbia Indians and their land. *West. Hist. Q.* 1991; 22: 500.
39. Wang LS, Narui T, Harada H, Culberson CF, Culberson WL. Ethnic uses of lichens in Yunnan, China. *Bryologist.* 2001; 104: 345-349.
40. Garibaldi A. Medicinal flora of the Alaska natives: A compilation of knowledge from literary sources of Aleut, Alutiq, Athabaskan, Eyak, Haida, Inupiat, Tlingit, Tsimshian, and Yupik traditional healing methods using plants. Alaska Natural Heritage Program, Environment and Natural Resources Institute, University of Alaska Anchorage. 1999.
41. Porter DM. *The names of plants*. Cambridge University Press, Cambridge. 1989.
42. Pieroni A, Dibra B, Grishaj G, Grishaj I, Maçai SG. Traditional phytotherapy of the Albanians of Lepushe, Northern Albanian alps. *Fitoterapia.* 2005; 76: 379-399.
43. Pieroni A. Medicinal plants and food medicines in the folk traditions of the upper Lucca Province, Italy. *J. Ethnopharmacol.* 2000; 70: 235-273.
44. Bugni TS, Andjelic CD, Pole AR, Rai P, Ireland CM, et al. Biologically active components of a Papua New Guinea analgesic and anti-inflammatory lichen preparation. *Fitoterapia.* 2009; 80: 270-273.
45. Yavuz M. Lichens in the Prescriptions of Pliny the Elder. *Oltenia. Stud. Şi. Comunicări. Ştiinţele. Nat.* 2013; 29: 115-119.
46. Scarpa GF. Medicinal plants used by the Criollos of Northwestern Argentine Chaco. *J. Ethnopharmacol.* 2004; 91: 115-135.
47. Silalahi M, Nisyawati, Walujo EB, Supriatna J, Mangunwardoyo W. The local knowledge of medicinal plants trader and diversity of medicinal plants in the Kabanjahe traditional market, North Sumatra, Indonesia. *J. Ethnopharmacol.* 2015; 175: 432-443.
48. Correche E, Kurdelas R, Lechon MJG, Cortes D, Freile ML, et al. Antibacterial, cytotoxic and antioxidant activities of extracts and secondary metabolites obtained from shrubs and lichens of Argentine. In: *Pharmacological applications of South America plants*. Research Signpost, Kerala, India. 2008: 112-123.
49. Ji H, Shengji P, Chunlin L. An ethnobotanical study of medicinal plants used by the Lisu people in Nujiang, Northwest Yunnan, China. *Econ. Bot.* 2004; 58: S253-264.
50. Yavuz M, Çobanoğlu G. Ethnological uses and etymology of the word Usnea in Ebubekir Razi's "Liber Almansoris". *Br. Lichen. Soc. Bull.* 2010; 106: 3-12.
51. Nugent-Head JA. The first materia medica: The shen nong ben cao jing. *J. Chin. Med.* 2014: 24-28.
52. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. *Semin. Oncol.* 2004; 31: 5-15.
53. González-Tejero MR, Martínez-Lirola MJ, Casares-Porcel M, Molero-Mesa J. Three lichens used in popular medicine in Eastern Andalusia (Spain). *Econ. Bot.* 1995: 96-98.
54. Marc EB, Nelly A, Annick DD, Frederic D. Plants used as remedies antirheumatic and antineuralgic in the traditional medicine of Lebanon. *J. Ethnopharmacol.* 2008; 120: 315-334.
55. Smith A. A contribution to South African materia medic: Chiefly from plants in use among the natives. *Botany.* 2011.
56. Scott LC. The medicinal and poisonous plants of Southern Africa. *Am. J. Trop. Med. Hyg.* 1933; 1: 544-545.
57. Elmore FH. *Ethnobotany of the Navajo: A monograph of the university of new Mexico and the school of American research*. School of American Research. 1944.
58. Silva JAC, Bomfim RR, Estevam CS, Antonioli ÂR, Araújo AAS, et al. Pharmacological properties of lichen *Cladonia clathrata*. *Pharm. Biol.* 2010; 48: 745-752.
59. Süleyman H, Odabasoglu F, Aslan A, Cakir A, Karagoz Y, et al. Anti-inflammatory and antiulcerogenic effects of the aqueous extract of *Lobaria pulmonaria* (L.) Hoffm. *Phytomedicine.* 2003; 10: 552-557.
60. Pereira EC, Da Silva HN, Santos RA, Sudário APP, Rodrigues E Silva AA, et al. Determination of teloschistes flavicans (sw) norm anti-inflammatory activity. *Pharmacognosy. Res.* 2010; 2: 205-210.
61. Ingolfsdottir K, Breu W, Huneck S, Gudjonsdottir GA, Müller-Jakic B, et al. In vitro inhibition of 5-lipoxygenase by protolich- esterinic acid from *Cetraria islandica*. *Phytomedicine.* 1994; 1: 187-191.
62. Ingolfsdottir K, Gissurarson SR, Muller-Jakic B, Breu W, Wagner H. Inhibitory effects of the lichen metabolite lobaric acid on arachidonate metabolism in vitro. *Phytomedicine.* 1996; 2: 243-246.
63. Min KR, Kim YK, Kang SH, Mar WC, Lee KS, Ro JS, et al. Inhibitory effects of herbal extracts on cyclooxygenase activity of prostaglandin H-2 synthase from sheep seminal vesicle. *Nat. Prod. Sci.* 1996; 2: 56-74.
64. Tatipamula VB, Vedula GS. Anti-inflammatory properties of *Dirinaria consimilis* extracts in albino rats. *J. Biomed. Sci.* 2018; 4: 3-8.
65. Tatipamula VB, Vedula GS. Fibrinolytic, anti-inflammatory and cytotoxic potentialities of extracts and chemical constituents of manglicolous lichen, *Graphis ajarekarii* Patw. & C. R. *Kulk. Nat. Prod. J.* 2020; 10: 87-93.
66. Tatipamula VB, Vedula GS, Sastry AVS. Chemical and pharmaco-

- logical evaluation of manglicolous lichen *Rocella montagnei* Bel em. D. D. Awasthi. *Futur. J. Pharm. Sci.* 2019; 5: 8.
67. Tatipamula VB, Vedula GS. In vitro anti-inflammatory and cytotoxicity studies of two mangrove associated lichens, *Dirinaria consimilis* and *Ramalina leiodea* extracts. *Hygeia. J. Drugs. Med.* 2018; 10: 16-26.
68. Dobrescu D, Tănăsescu M, Mezdrea A, Ivan C, Ordosch E, et al. Contributions to the complex study of some lichens-*Usnea* genus. Pharmacological studies on *Usnea barbata* and *Usnea hirta* species. *Rom. J. Physiol. Physiol. Sci.* 1993; 30: 101-107.
69. Stocker-Wörgötter E. Metabolic diversity of lichen-forming ascomycetous fungi: Culturing, polyketide and shikimate metabolite production, and PKS genes. *Nat. Prod. Rep.* 2008; 25: 188-200.
70. Prokopiev IA, Poryadina LN, Konoreva LA, Chesnokov SV, Shavarda AL. Variation in the composition of secondary metabolites in *Flavocetraria* lichens from Western Siberia. *Russ. J. Ecol.* 2018; 49: 401-405.
71. Ranković B, Kosanić M. Lichens as a potential source of bioactive secondary metabolites. In: *Lichen secondary metabolites: Bioactive properties and pharmaceutical potential.* Springer, Cham. 2019: 1-29.
72. Tatipamula VB, Vedula GS. Antimicrobial and anti-tubercular activities of isolates and semi-synthetic derivatives of lichen *Ramalina leiodea* (Nyl.) Nyl. *J. Serbian. Chem. Soc.* 2019; 84: 555-562.
73. Tatipamula VB, Vedula GS, Rathod BB, Shetty PR. Study of phytochemical analysis, total flavonoid and phenolic content, antimicrobial properties and chemical constituents of two manglicolous lichens extracts. *Inven. Rapid. Planta. Act.* 2018; 2018: 129-134.
74. Tatipamula VB, Vedula GS, Sastry AVS. Antiarvedisides A-B from manglicolous lichen *Dirinaria consimilis* (Stirton) and their pharmacological profile. *Asian. J. Chem.* 2019; 31: 805-812.
75. Haritha P, Patnaik SK, Tatipamula VB. Chemical and pharmacological evaluation of manglicolous lichen *Graphis ajarekarii* Patw. & C. R. Kulk. *Vietnam. J. Sci. Technol.* 2019; 53: 300-308.
76. Tatipamula VB, Annam SSP, Nguyen HT, Polimati H, Yejella RP. Sekikaic acid modulates pancreatic β -cells in streptozotocin-induced type 2 diabetic rats by inhibiting digestive enzymes. *Nat. Prod. Res.* 2020: 1-5.
77. Shibuya M, Ebizuka Y, Noguchi H, Iitaka Y, Sankawa U. Inhibition of prostaglandin biosynthesis by 4-O-methylcryptochlorophaeic acid; synthesis of monomeric arylcarboxylic acids for inhibitory activity testing and X-ray analysis of 4-O-methylcryptochlorophaeic acid. *Chem. Pharm. Bull. (Tokyo).* 1983; 31: 407-413.
78. Sankawa U, Shibuya M, Ebizuka Y, Noguchi H, Iitaka Y, et al. Depside as potent inhibitor of prostaglandin biosynthesis: A new active site model for fatty acid cyclooxygenase. *Prostaglandins.* 1982; 24: 21-34.
79. Melo MGD, Araújo AAS, Serafini MR, Carvalho LF, Bezerra MS, et al. Anti-inflammatory and toxicity studies of atranorin extracted from *Cladonia kalbii* Ahti in rodents. *Brazilian. J. Pharm. Sci.* 2011; 47: 861-872.
80. Kumar KCS, Müller K. Lichen Metabolites. 1. Inhibitory action against leukotriene B 4 biosynthesis by a non-redox mechanism. *J. Nat. Prod.* 1999; 62: 817-820.
81. Ingólfssdóttir K, Wiedemann B, Birgisdóttir M, Nenninger A, Jónsdóttir S, et al. Inhibitory effects of baeomycesic acid from the lichen *Thamnolia subuliformis* on 5-lipoxygenase in vitro. *Phyto-medicine.* 1997; 4: 125-128.
82. Gissurarson SR, Sigurdsson SB, Wagner H, Ingólfssdóttir K. Effect of lobaric acid on cysteinyl-leukotriene formation and contractile activity of guinea pig taenia coli. *J. Pharmacol. Exp. Ther.* 1997; 280: 770-773.
83. Tatipamula VB, Polimati H, Gopaiah KV, Babu AK, Vantaku S, et al. Bioactive metabolites from manglicolous lichen *Ramalina leiodea* (Nyl.) Nyl. *Indian. J. Pharm. Sci.* 2020; 82: 379-384.
84. Tatipamula VB, Ketha A. Manglicolous lichen *Parmotrema tinctorum* (Despr. ex Nyl.) Hale: Isolation, characterization and biological evaluation. *Indian. J. Chem-Sect. B.* 2020; 59B: 856-861.